Table 3.
Clinical features of ILD
| Patient | Age (years) | Gender | Histology | ICIs | Response | ILD Grade | Time to ILD (Days) | Pre‐existing IP | Radiologic pattern | Histopathological findings of ILD | Treatment | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Case 1 | 82 | Male | Ad | Nivolumab | SD | 3 | 21 | No | OP | OP | Steroid pulse | Improved |
| Case 2 | 76 | Male | Sq | Nivolumab | PR | 3 | 32 | No | OP | — | Steroid pulse Cyclophosphamide | Improved |
| Case 3 | 72 | Female | Sq | Nivolumab | PR | 3 | 57 | Yes | OP | — | Steroid pulse Cyclophosphamide | Improved |
| Case 4 | 75 | Male | Ad | Nivolumab | PR | 3 | 150 | No | OP | OP | Steroid pulse | Improved |
| Case 5 | 63 | Female | Ad | Nivolumab | PR | 1 | 74 | No | OP | — | None | Improved |
| Case 6 | 61 | Male | Sq | Nivolumab | NE | 5 | 6 | Yes | DAD | — | Steroid pulse Cyclophosphamide | Died |
| Case 7 | 74 | Male | Sq | Nivolumab | PR | 5 | 314 | No | OP | — | Steroid pulse Cyclophosphamide | Died |
| Case 8 | 73 | Male | Sq | Pembrolizumab | PD | 3 | 7 | No | HP | — | Steroid pulse | Improved |
| Case 9 | 82 | Male | Pleomorphic | Pembrolizumab | PR | 2 | 68 | No | OP | OP | None | Improved |
| Case 10 | 69 | Female | Sq | Pembrolizumab | PR | 3 | 12 | No | NOS | Cellular alveolitis | Steroid pulse | Improved |
| Case 11 | 68 | Female | Ad | Pembrolizumab | PR | 3 | 94 | No | OP | Cellular alveolitis | Oral prednisolone 1 mg/kg | Improved |
| Case 12 | 80 | Male | NSCLC | Pembrolizumab | PR | 2 | 227 | No | OP | — | Oral prednisolone 1 mg/kg | Improved |
| Case 13 | 80 | Male | Sq | Pembrolizumab | NE | 5 | 28 | Yes | DAD | — | Steroid pulse Cyclophosphamide | Died |
| Case 14 | 70 | Male | Ad | Atezolizumab | SD | 3 | 7 | Yes | NOS | — | Steroid half pulse | Improved |
| Case 15 | 75 | Female | Ad | Atezolizumab | PD | 1 | 42 | No | NOS | — | None | Improved |
| Case 16 | 80 | Male | Sq | Atezolizumab | PR | 1 | 23 | No | NOS | — | None | Improved |
Ad, adeno; DAD, diffuse alveolar damage; GGO, ground‐glass opacities; ILD, interstitial lung disease; IP, interstitial pneumonia; NE; not evaluable; NOS, not otherwise specified; NSCLC, non‐small cell lung cancer; OP, organizing pneumonia; PR, partial response; SD, stable disease; Sq, squamous.